Read-Gene S.A. (WSE:RDG)

Read-Gene Statistics

Total Valuation

Read-Gene has a market cap or net worth of PLN 61.78 million. The enterprise value is 64.91 million.

Market Cap	61.78M
Enterprise Value	64.91M

Important Dates

The next confirmed earnings date is Wednesday, May 13, 2026.

Earnings Date	May 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Read-Gene has 11.79 million shares outstanding.

Current Share Class	1.49M
Shares Outstanding	11.79M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	7.16%
Owned by Institutions (%)	n/a
Float	1.27M

Valuation Ratios

The trailing PE ratio is 76.43.

PE Ratio	76.43
Forward PE	n/a
PS Ratio	3.97
PB Ratio	16.16
P/TBV Ratio	16.16
P/FCF Ratio	n/a
P/OCF Ratio	306.37
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 43.46, with an EV/FCF ratio of -508.90.

EV / Earnings	80.31
EV / Sales	4.17
EV / EBITDA	43.46
EV / EBIT	62.27
EV / FCF	-508.90

Financial Position

The company has a current ratio of 7.58, with a Debt / Equity ratio of 2.17.

Current Ratio	7.58
Quick Ratio	7.52
Debt / Equity	2.17
Debt / EBITDA	5.56
Debt / FCF	-65.04
Interest Coverage	3.15

Financial Efficiency

Return on equity (ROE) is 23.64% and return on invested capital (ROIC) is 17.02%.

Return on Equity (ROE)	23.64%
Return on Assets (ROA)	4.34%
Return on Invested Capital (ROIC)	17.02%
Return on Capital Employed (ROCE)	7.40%
Weighted Average Cost of Capital (WACC)	6.55%
Revenue Per Employee	778,431
Profits Per Employee	40,416
Employee Count	20
Asset Turnover	1.04
Inventory Turnover	10.34

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +16.96% in the last 52 weeks. The beta is 0.50, so Read-Gene's price volatility has been lower than the market average.

Beta (5Y)	0.50
52-Week Price Change	+16.96%
50-Day Moving Average	5.60
200-Day Moving Average	5.56
Relative Strength Index (RSI)	41.40
Average Volume (20 Days)	310

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Read-Gene had revenue of PLN 15.57 million and earned 808,327 in profits. Earnings per share was 0.07.

Revenue	15.57M
Gross Profit	14.57M
Operating Income	1.04M
Pretax Income	808,327
Net Income	808,327
EBITDA	1.49M
EBIT	1.04M
Earnings Per Share (EPS)	0.07

Balance Sheet

The company has 5.16 million in cash and 8.30 million in debt, with a net cash position of -3.13 million or -0.27 per share.

Cash & Cash Equivalents	5.16M
Total Debt	8.30M
Net Cash	-3.13M
Net Cash Per Share	-0.27
Equity (Book Value)	3.82M
Book Value Per Share	0.32
Working Capital	8.33M

Cash Flow

In the last 12 months, operating cash flow was 201,650 and capital expenditures -329,205, giving a free cash flow of -127,555.

Operating Cash Flow	201,650
Capital Expenditures	-329,205
Depreciation & Amortization	451,077
Net Borrowing	n/a
Free Cash Flow	-127,555
FCF Per Share	-0.01

Margins

Gross margin is 93.56%, with operating and profit margins of 6.70% and 5.19%.

Gross Margin	93.56%
Operating Margin	6.70%
Pretax Margin	5.19%
Profit Margin	5.19%
EBITDA Margin	9.59%
EBIT Margin	6.70%
FCF Margin	n/a

Dividends & Yields

Read-Gene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	1.31%
FCF Yield	-0.21%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Read-Gene has an Altman Z-Score of 4.83 and a Piotroski F-Score of 6.

Altman Z-Score	4.83
Piotroski F-Score	6